SEC Form 4 · accession 0001437749-17-000155
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeff R. Schroeder
Officer — Chief Commercial Officer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Jan 3, 2017 | M | 13,783 | $0.09 | A | 70,864 | D | |
| Ordinary Shares | Jan 3, 2017 | M | 22,371 | $0.09 | A | 93,235 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $0.09 | Jan 3, 2017 | M | 13,783 | A | — | Feb 11, 2017 | Ordinary Shares | 13,783 | 0 | D |
| Share Option (Right to Buy)F2 | $0.09 | Jan 3, 2017 | M | 22,371 | A | — | Oct 23, 2017 | Ordinary Shares | 22,371 | 0 | D |
Explanation of responses
- F1Options became fully exercisable on February 11, 2011.
- F2Options became fully exercisable on October 23, 2011